Drug-eluting stents in primary PCI [3]

New England Journal of Medicine

Volumn 355, Issue 23, 2006, Pages 2484-

  Valgimigli, Marco ^a   Percoco, Gianfranco ^a   Bolognese, Leonardo ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; RAPAMYCIN;

ANGIOCARDIOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PACLITAXEL; PATIENT SELECTION; RESEARCH DESIGN; SIROLIMUS; STENTS;

EID: 33845411916     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.
2. Suryapranata H, De Luca G, van't Hof AW, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart 2005;91:641-5.